Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | ALPL | P05186 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1036692 | 0.86 | ALPL (0.52) | TRPV4SMN1; SMN2ALDH1A1ALPLKMT2A | |
| SCHEMBL4944543 | 0.82 | SMN1; SMN2 (0.56) | TRPV4SMN1; SMN2ALDH1A1ALPLKMT2A | |
| SCHEMBL31525522 | 0.80 | TRPV4 (0.47) | TRPV4SMN1; SMN2ALDH1A1ALPLKMT2A | |
| SCHEMBL10642296 | 0.77 | TRPV4 (0.45) | TRPV4SMN1; SMN2ALDH1A1ALPLKMT2A | |
| SCHEMBL8646151 | 0.77 | TRPV4 (0.45) | TRPV4SMN1; SMN2ALDH1A1ALPLKMT2A | |
| SCHEMBL4183325 | 0.75 | TSHR (0.51) | SMN1; SMN2ALDH1A1ALPLKMT2AMEN1 | |
| SCHEMBL15220366 | 0.74 | ALPL (0.51) | TRPV4SMN1; SMN2ALPLKMT2AMAPK1 | |
| SCHEMBL4201928 | 0.74 | SMN1; SMN2 (0.50) | TRPV4SMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL5348639 | 0.74 | TRPV4 (0.57) | TRPV4SMN1; SMN2ALDH1A1ALPLKMT2A | |
| SCHEMBL1127669 | 0.74 | KDM4E (0.59) | TRPV4SMN1; SMN2ALPLKMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247536-A1 | Bissulfonamide Compounds As Agonists Of GalR1, Compositions, And Methods Of Use | MJALLI ADNAN M M | 2009-10-01 | — | — | US | disclosed |
| US-7582673-B2 | Benzo[b]thiophene-2-sulfonic acid [2-(2-chloro-5-trifluoromethylbenzenesulfonylamino)phenyl] amide; agonists of GalR1; useful in treating neuropathic pain or cancer | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-09-01 | — | — | US | disclosed |
| EP-1809619-A1 | BISSULFONAMIDE COMPOUNDS AS AGONISTS OF GALR1, COMPOSITIONS, AND METHODS OF USE | Transtech Pharma, Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060106089-A1 | Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use | VTVX HOLDINGS II LLC | 2006-05-18 | — | — | US | disclosed |
| WO-2006047302-A1 | BISSULFONAMIDE COMPOUNDS AS AGONISTS OF GALR1, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106089-A1 | Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use | GALR1, GALR3, GALR2 | TRPV4 626/4885SMN1; SMN2 1898/4885ALDH1A1 4001/4885 |
| US-20090247536-A1 | Bissulfonamide Compounds As Agonists Of GalR1, Compositions, And Methods Of Use | GALR1, GALR3, GALR2 | TRPV4 626/4885SMN1; SMN2 1898/4885ALDH1A1 4001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.